Ameriprise Financial Inc. Has $6.46 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Ameriprise Financial Inc. decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 12.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 139,067 shares of the company's stock after selling 19,053 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.23% of Twist Bioscience worth $6,462,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of TWST. Van ECK Associates Corp lifted its stake in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. US Bancorp DE lifted its stake in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. KBC Group NV lifted its stake in shares of Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at $209,000. Finally, Blue Trust Inc. lifted its stake in shares of Twist Bioscience by 19.9% in the 4th quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock valued at $206,000 after purchasing an additional 757 shares during the last quarter.

Insider Activity

In other news, SVP Paula Green sold 918 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the transaction, the senior vice president now owns 130,912 shares of the company's stock, valued at $5,355,609.92. The trade was a 0.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,726 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the transaction, the chief executive officer now directly owns 660,966 shares of the company's stock, valued at $27,549,062.88. This trade represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,011 shares of company stock worth $951,499. Insiders own 3.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Barclays reduced their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Robert W. Baird cut their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. cut their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group cut their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $50.40.

Twist Bioscience Stock Performance

Shares of TWST traded down $0.32 during trading hours on Wednesday, reaching $29.09. 141,175 shares of the company traded hands, compared to its average volume of 975,508. The stock's fifty day moving average is $36.19 and its 200 day moving average is $42.60. The stock has a market cap of $1.74 billion, a P/E ratio of -8.63 and a beta of 2.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 1-year low of $27.12 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $92.79 million during the quarter, compared to the consensus estimate of $92.00 million. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.